(RAYNHAM, Mass., February 17, 2004) --
DePuy Spine, Inc., a Johnson & Johnson
company, reported Tuesday it has submitted
a Premarket Approval Application (PMA) to
the U.S. Food
and Drug Administration (FDA) for review of its CHARITÉ™ Artificial
Disc.
The company's
submission includes results of a 375-patient clinical study comparing
implantation
of the CHARITÉ™ Artificial Disc to spinal
fusion surgery for the treatment of degenerative disc disease.
"We believe the CHARITÉ™ Artificial Disc's motion
preservation technology has the potential to transform the treatment
of spine disorders
in the United States," said Earl R. Fender, worldwide president,
DePuy Spine, Inc. "We also believe this first-ever submission
for a total disc replacement device represents what could be the beginning
of a promising era of new treatment of physiologically desirable options
for degenerative disc disease."
The CHARITÉ™ Artificial Disc has been used to treat more
than 6,500 patients over the past 15 years in 30 countries outside
the United
States. FDA approval of the CHARITÉ™ Artificial Disc
would provide doctors and patients an alternative to spinal fusion
surgery*,
which is
performed on more than 300,000 people each year in the United States.
"We are pleased with the contents of the submission and feel
that the data soundly supports the study hypothesis for outcome equivalency,"
said Bill Christianson, vice president, Clinical & Regulatory Affairs,
DePuy Spine, Inc. "The primary outcome results for the CHARITÉ™ patients
compared well with the results of patients within the clinical study's
fusion control group."
The CHARITÉ™ Artificial Disc is made of two metallic
endplates and a polyethylene core that articulates between them and
has been the
subject of clinical trials at 15 centers throughout the United States.
DePuy Spine, Inc., acquired Link Spine Group and the CHARITÉ™
Artificial Disc, including exclusive worldwide rights to the product,
in May 2003.
About DePuy Spine, Inc.
DePuy Spine, Inc., a Johnson & Johnson company, has partnered with
leading clinicians, researchers and thought leaders to develop products
to treat spine disorders for over 20 years. Today, DePuy Spine, Inc.,
stands in the forefront of the worldwide spine market, with a substantial
sales organization in the U.S. and an expanding worldwide distribution
network. The company is committed to advancing the knowledge of all health
care professionals and their patients in addressing spinal pathologies.
*Spinal fusion is a technique in which one or more unstable spinal
vertebrae on the spine are immobilized, using bone graft material. While
this may help reduce or stop back pain, spinal fusion limits the patient's
range of motion and may unnaturally stress the adjacent anatomy.